Over time, backup systems can develop weaknesses that only become apparent under real operating stress. UPS systems are particularly susceptible to gradual degradation. As valve-regulated lead-acid or lithium-ion batteries age, internal resistance increases and discharge capacity declines. This can result in voltage sag or brief interruptions capable of tripping sensitive PLCs, environmental controls or aseptic systems – threatening batch integrity even when primary equipment remains functional. Generators present different risks. Emergency
nplanned downtime remains one of manufacturing’s greatest risks, and in pharmaceutical production it can result
in severe consequences. Modern therapies, including monoclonal antibodies, vaccines, advanced cell and gene therapies, are developed through laboratory- scale processes before being scaled for commercial manufacture. This transition involves tightly regulated, highly complex operations where every stage, from cell growth and purification to formulation and packaging, must be precisely controlled. Power fluctuations during bioreactor runs
can destroy weeks of cell culture. Lapses in airflow or pressure on aseptic fill-finish lines can trigger requalification, while interruptions to chromatography or lyophilisation may render entire batches unusable. Deviations can also result in non-compliance with GMP or MHRA requirements, leading to batch rejection. Downtime delays can also result in
bottlenecks that affect hospitals, pharmacies and clinics, and can directly impact patient treatment schedules and outcomes. Furthermore, downtime events in pharmaceutical manufacturing often last eight hours or more, with costs estimated at £5–10 million per incident.
34
Pharmaceutical plants rely on carefully engineered backup power systems combining standby generators, uninterruptible power supplies (UPS) and battery storage and redundancy. In practice, generators provide sustained
electricity during extended outages, keeping essential manufacturing systems operational until grid power is restored. UPS systems deliver instantaneous power during the critical seconds required for generators to start and synchronise, preventing interruption to sensitive processes. Battery storage further stabilises supply by absorbing voltage dips, extending UPS runtime or supporting particularly critical circuits. Redundancy is also designed into these
systems to ensure continuity if a single component fails. This may include dual generators, parallel UPS configurations or segregated power distribution circuits isolating essential equipment. Additional considerations, such as selective coordination, fault-clearing times and compliance with IEC 60364 or BS 7671, help ensure system stability under abnormal grid conditions. While these arrangements provide multiple
layers of protection, even well-designed backup power systems can fail without proper validation.
loads in pharmaceutical facilities are often low and stable, meaning generators frequently operate below rated capacity during routine testing. Chronic underloading can lead to wet stacking, where unburned fuel accumulates in the exhaust system. During an actual outage, this may cause slow load acceptance, frequency instability or voltage drops affecting motors that drive bioreactors, pumps or centrifuges. Ageing transfer switches, harmonics, corroded
connections or poorly integrated upgrades can introduce resistance or distortion. Systems may pass inspections yet fail under full load, making proactive, high-fidelity testing essential. As a result, systems may pass routine inspections yet fail during sustained or full-load operation, making proactive, high-fidelity testing essential.
Load bank testing provides pharmaceutical manufacturers with a controlled, measurable way to replicate the electrical loads and stresses backup power systems would experience during a real outage. During testing, electrical load is applied to generators or UPS systems to simulate full facility demand or critical sub- system loads. Engineers can then assess voltage and frequency stability, step-load response, transfer times, thermal behaviour, fuel consumption and sustained performance. This approach reveals issues such as wet
stacking, UPS voltage sag, overheating cables or slow transfer switches that low-load testing cannot detect. Different load bank types allow accurate simulation of real operating conditions. Resistive load banks apply steady-state loads reflecting baseline demand, while reactive load banks replicate equipment with variable power factors. Dynamic load banks simulate rapid load changes such as motor starts, inrush currents and transient surges typical of pharmaceutical processes. Because simulated loads cannot be routed
into live facilities, load banks safely absorb and dissipate generated energy using high-capacity ballast elements. Advanced programmable systems, such as Digiload, can reproduce complex load profiles that mirror real plant behaviour, transforming load bank testing into a predictive tool for modelling realistic outage scenarios. Load bank testing therefore gives
manufacturers confidence that backup power will perform, protecting therapies and ensuring medicines reach patients.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
